Amaro, Adriana
Reggiani, Francesco
Fenoglio, Daniela
Gangemi, Rosaria
Tosi, Anna
Parodi, Alessia
Banelli, Barbara
Rigo, Valentina
Mastracci, Luca
Grillo, Federica
Cereghetti, Alessandra
Tastanova, Aizhan
Ghosh, Adhideb
Sallustio, Fabio
Emionite, Laura
Daga, Antonio
Altosole, Tiziana
Filaci, Gilberto
Rosato, Antonio
Levesque, Mitchell
Maio, Michele
Pfeffer, Ulrich http://orcid.org/0000-0003-0872-4671
Croce, Michela
,
Funding for this research was provided by:
Ministero della Salute
Associazione Italiana per la Ricerca sul Cancro (21073, 21073)
Article History
Received: 23 December 2022
Accepted: 21 February 2023
First Online: 18 March 2023
Declarations
:
: Not applicable.
: All authors have approved the submitted version (and any substantially modified version that involves the author’s contribution to the study). All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.
: Michele Maio has served as a consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and own shares in Theravance and Epigen Therapeutics, Srl. The other authors declare that they have no competing interests.